19-Nor-4-hydroxyabieta-8,11,13-trien-7-oneCAS# 57906-31-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 57906-31-7 | SDF | Download SDF |
PubChem ID | 91884799 | Appearance | Powder |
Formula | C19H26O2 | M.Wt | 286.4 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (1S,4aS,10aR)-1-hydroxy-1,4a-dimethyl-7-propan-2-yl-3,4,10,10a-tetrahydro-2H-phenanthren-9-one | ||
SMILES | CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2=O)(C)O)C | ||
Standard InChIKey | PTQFIYQNKVSVGM-QRVBRYPASA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one Dilution Calculator
19-Nor-4-hydroxyabieta-8,11,13-trien-7-one Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4916 mL | 17.4581 mL | 34.9162 mL | 69.8324 mL | 87.2905 mL |
5 mM | 0.6983 mL | 3.4916 mL | 6.9832 mL | 13.9665 mL | 17.4581 mL |
10 mM | 0.3492 mL | 1.7458 mL | 3.4916 mL | 6.9832 mL | 8.7291 mL |
50 mM | 0.0698 mL | 0.3492 mL | 0.6983 mL | 1.3966 mL | 1.7458 mL |
100 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.6983 mL | 0.8729 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- o-Anisic acid
Catalog No.:BCC9108
CAS No.:579-75-9
- Lobelanine
Catalog No.:BCN2156
CAS No.:579-21-5
- Oligomycin A
Catalog No.:BCC2530
CAS No.:579-13-5
- Myrianthic acid 3,23-acetonide
Catalog No.:BCN7517
CAS No.:578710-52-8
- Clozapine
Catalog No.:BCC5037
CAS No.:5786-21-0
- Idarubicin HCl
Catalog No.:BCC1194
CAS No.:57852-57-0
- Stevioside
Catalog No.:BCN6305
CAS No.:57817-89-7
- Domperidone
Catalog No.:BCC4461
CAS No.:57808-66-9
- Liquiritigenin
Catalog No.:BCN5946
CAS No.:578-86-9
- Cosmosiin
Catalog No.:BCN5788
CAS No.:578-74-5
- 8-Aminoquinoline
Catalog No.:BCC8784
CAS No.:578-66-5
- 4-(2-Hydroxy-1-methoxyethyl)-1,2-benzenediol
Catalog No.:BCN1412
CAS No.:577976-26-2
- Corynoxidine
Catalog No.:BCN6798
CAS No.:57906-85-1
- Z-Cys(Z)-OH
Catalog No.:BCC2784
CAS No.:57912-35-3
- L(+)-Asparagine Monohydrate
Catalog No.:BCC8332
CAS No.:5794-13-8
- Officinalisinin I
Catalog No.:BCN2825
CAS No.:57944-18-0
- Bax inhibitor peptide V5
Catalog No.:BCC2394
CAS No.:579492-81-2
- Bax inhibitor peptide P5
Catalog No.:BCC2393
CAS No.:579492-83-4
- Caffeine
Catalog No.:BCN5807
CAS No.:58-08-2
- Pyrimethamine
Catalog No.:BCC2307
CAS No.:58-14-0
- Aminophenazone
Catalog No.:BCC8815
CAS No.:58-15-1
- Methyltestosterone
Catalog No.:BCC9045
CAS No.:58-18-4
- Testosterone cypionate
Catalog No.:BCC9167
CAS No.:58-20-8
- Testosterone
Catalog No.:BCN2193
CAS No.:58-22-0
Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample.[Pubmed:28381479]
Diabetes Care. 2017 Jun;40(6):751-758.
OBJECTIVE: The aim of this study was to examine whether insulin resistance, assessed by HOMA of insulin resistance (HOMA-IR), is an independent predictor of cognitive decline. RESEARCH DESIGN AND METHODS: The roles of HOMA-IR, fasting insulin and glucose, HbA1c, and hs-CRP as predictors of cognitive performance and its change were evaluated in the Finnish nationwide, population-based Health 2000 Health Examination Survey and its 11-year follow-up, the Health 2011 study (n = 3,695, mean age at baseline 49.3 years, 55.5% women). Categorical verbal fluency, word-list learning, and word-list delayed recall were used as measures of cognitive function. Multivariate linear regression analysis was performed and adjusted for previously reported risk factors for cognitive decline. RESULTS: Higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P = 0.0002 for both) and of a greater decline in verbal fluency during the follow-up time (P = 0.004 for both). Baseline HOMA-IR and insulin did not predict word-list learning or word-list delayed recall scores. There were no interactions between HOMA-IR and apolipoprotein E epsilon4 (APOEepsilon4) genotype, hs-CRP, or type 2 diabetes on the cognitive tests. Fasting glucose and hs-CRP levels at baseline were not associated with cognitive functioning. CONCLUSIONS: Our results show that higher serum fasting insulin and insulin resistance predict poorer verbal fluency and a steeper decline in verbal fluency during 11 years in a representative sample of an adult population. Prevention and treatment of insulin resistance might help reduce cognitive decline later in life.
GNG11 (G-protein subunit gamma 11) suppresses cell growth with induction of reactive oxygen species and abnormal nuclear morphology in human SUSM-1 cells.[Pubmed:28380310]
Biochem Cell Biol. 2017 Aug;95(4):517-523.
Enforced expression of GNG11, G-protein subunit gamma 11, induces cellular senescence in normal human diploid fibroblasts. We here examined the effect of the expression of GNG11 on the growth of immortalized human cell lines, and found that it suppressed the growth of SUSM-1 cells, but not of HeLa cells. We then compared these two cell lines to understand the molecular basis for the action of GNG11. We found that expression of GNG11 induced the generation of reactive oxygen species (ROS) and abnormal nuclear morphology in SUSM-1 cells but not in HeLa cells. Increased ROS generation by GNG11 would likely be caused by the down-regulation of the antioxidant enzymes in SUSM-1 cells. We also found that SUSM-1 cells, even under normal culture conditions, showed higher levels of ROS and higher incidence of abnormal nuclear morphology than HeLa cells, and that abnormal nuclear morphology was relevant to the increased ROS generation in SUSM-1 cells. Thus, SUSM-1 and HeLa cells showed differences in the regulation of ROS and nuclear morphology, which might account for their different responses to the expression of GNG11. Thus, SUSM-1 cells may provide a unique system to study the regulatory relationship between ROS generation, nuclear morphology, and G-protein signaling.
Access to percutaneous transluminal coronary angioplasty and 30-day mortality in patients with incident STEMI: Differentials by educational level and gender over 11 years.[Pubmed:28384181]
PLoS One. 2017 Apr 6;12(4):e0175038.
BACKGROUND: Socioeconomic status and gender are associated with access to cardiac procedures and mortality after AMI, also in countries with universal health care systems. Our objective was to evaluate the association and trends of educational level or gender and the following outcomes: 1) access to PTCA; 2) 30-day mortality. METHODS: We conducted an observational study based on 14,013 subjects aged 35-74 years, residing in Rome in 2001, and hospitalised for incident STEMI within 2012 in the Lazio region. We estimated adjusted ORs of educational level or gender and: 1) PTCA within 2 days after hospitalisation, 2) 30-day mortality. We evaluated time trends of outcomes, and time trends of educational or gender differentials estimating ORs stratified by time period (two time periods between 2001 and 2012). We performed a hierarchical analysis to account for clustering of hospitals. RESULTS: Access to PTCA among patients with incident STEMI increased during the study period, while 30-day mortality was stable. We observed educational differentials in PTCA procedure only in the first time period, and gender differentials in both periods. Patterns for 30-day mortality were less marked, with educational differentials emerging only in the second period, and gender differentials only in the first one, with patients with low educational level and females being disadvantaged. CONCLUSIONS: Educational differentials in the access to PTCA disappeared in Lazio region over time, coherently with scientific literature, while gender differentials seem to persist. It may be important to assess the role of female gender in patients with STEMI, both from a social and a clinical point of view.
Simultaneous quantification of 11 active constituents in Shexiang Baoxin Pill by ultraperformance convergence chromatography combined with tandem mass spectrometry.[Pubmed:28384605]
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:135-141.
On account of the complexity of chemical constituents of Shexiang Baoxin Pill (SBP), a famous traditional Chinese medicine (TCM) formula, a novel and effective UPC(2)-MS/MS method was developed to simultaneously determine the content of 11 active compounds of SBP with outstanding separation ability. Eleven components in SBP, including 2 ginsenosides, 2 bile acids, 3 bufadienolides and 4 volatiles were detected by electrospray ionization tandem mass spectrometry in positive and negative ion modes with multiple reaction monitor (MRM). The analysis was performed at 30 degrees C using an Acquity UPC(2) Diol (3.0x50mm, 1.7mum) column with linear gradient elution (eluent A, CO2; eluent B, methanol containing 20mM ammonium acetate), back pressure of 2000 psi, flow rate of 1.2mL/min and the injection volume of 1.0muL. The method was extensively validated regarding the linearity (r>/=0.9974), precision (=3.11%), recovery (93.34-104.50%), repeatability (=2.00%) and stability (=4.20%). Using this method, 11 active compounds of SBP with different polarity were simultaneously quantified in one chromatography analysis within 8min. Statistical analysis of the effects of 11 compounds on the quality of SBP revealed that the content of cinnamaldehyde varied widely in different batches. This work presents an exemplary study for quality control of complex samples, especially for TCMs.